Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020
SHANGHAI and SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed clinical data from the NORA Phase 3 study of niraparib have been accepted as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress. Details of the oral presentation are as follows:
Title: Individualized Starting Dose of Niraparib in Chinese Patients with Platinum-Sensitive Recurrent Ovarian Cancer (PSROC): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial (NORA)
Presentation Number: LBA29
Lecture Time: September 19, 2020, 13:14-13:26 Central European Summer Time
Presenter: Dr. Xiaohua Wu, Professor and Chair of Gynecologic Oncology Department of Fudan University Shanghai Cancer Centre
About Zai Lab
Zai Lab (NASDAQ:ZLAB) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China’s pharmaceutical market and address unmet medical needs, Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.
For additional information about the company, please visit or follow us at /ZaiLab_Global.
For more information, please contact:
ZAI LAB CONTACTS:
Zai Lab
Billy Cho, CFO
01
Media: Ryo Imai / Robert Flamm, Ph.D.
Burns McClellan, on behalf of Zai Lab
212-213-0006 ext. 315 / 364
/
Investors: Pete Rahmer / Mike Zanoni
Endurance Advisors, on behalf of Zai Lab
415-515-9763 / 610-442-8570
/
Zai Lab Limited
